Soleno Therapeutics, Inc.
SLNO
$73.64
$0.380.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 105.86M | 72.70M | 26.82M | 19.10M | 13.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 184.43M | 138.47M | 68.50M | 53.57M | 38.67M |
| Operating Income | -184.43M | -138.47M | -68.50M | -53.57M | -38.67M |
| Income Before Tax | -175.85M | -131.16M | -65.41M | -52.03M | -38.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -175.85 | -131.16 | -65.41 | -52.03 | -38.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -175.85M | -131.16M | -65.41M | -52.03M | -38.99M |
| EBIT | -184.43M | -138.47M | -68.50M | -53.57M | -38.67M |
| EBITDA | -182.44M | -136.50M | -66.53M | -51.62M | -36.71M |
| EPS Basic | -4.26 | -3.31 | -2.43 | -2.68 | -2.98 |
| Normalized Basic EPS | -2.61 | -2.01 | -1.41 | -1.57 | -1.75 |
| EPS Diluted | -4.27 | -3.32 | -2.44 | -2.68 | -2.98 |
| Normalized Diluted EPS | -2.61 | -2.01 | -1.41 | -1.57 | -1.75 |
| Average Basic Shares Outstanding | 160.64M | 151.16M | 120.72M | 92.51M | 65.75M |
| Average Diluted Shares Outstanding | 160.64M | 151.16M | 120.72M | 92.51M | 65.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |